157 related articles for article (PubMed ID: 27124800)
21. Treatment Patterns and Survival Outcomes in Patients With Follicular Lymphoma: A 2007 to 2015 Humedica Database Study.
Morrison VA; Shou Y; Bell JA; Hamilton L; Ogbonnaya A; Raju A; Hennenfent K; Eaddy M; Galaznik A
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):e172-e183. PubMed ID: 30691994
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics and outcomes of relapsed follicular lymphoma after autologous stem cell transplantation in the rituximab era.
Sesques P; Bourcier J; Golfier C; Lebras L; Nicolas-Virelizier E; Hacini M; Perrin MC; Voillat L; Bachy E; Traverse-Glehen A; Moreau A; Martin L; Ramla S; Casasnovas O; Le Gouill S; Salles G; Ghesquières H
Hematol Oncol; 2020 Apr; 38(2):137-145. PubMed ID: 31953963
[TBL] [Abstract][Full Text] [Related]
23. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience.
Tan D; Horning SJ; Hoppe RT; Levy R; Rosenberg SA; Sigal BM; Warnke RA; Natkunam Y; Han SS; Yuen A; Plevritis SK; Advani RH
Blood; 2013 Aug; 122(6):981-7. PubMed ID: 23777769
[TBL] [Abstract][Full Text] [Related]
24. Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.
Nicolas-Virelizier E; Ségura-Ferlay C; Ghesquières H; Chassagne-Clément C; Gargi T; Biron P; Belhabri A; Rey P; Faurie P; Chabaud S; Sebban C
Hematol Oncol; 2015 Mar; 33(1):1-8. PubMed ID: 24496668
[TBL] [Abstract][Full Text] [Related]
25. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
[TBL] [Abstract][Full Text] [Related]
26. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).
Wagner-Johnston ND; Link BK; Byrtek M; Dawson KL; Hainsworth J; Flowers CR; Friedberg JW; Bartlett NL
Blood; 2015 Aug; 126(7):851-7. PubMed ID: 26105149
[TBL] [Abstract][Full Text] [Related]
27. Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study.
Martin P; Byrtek M; Dawson K; Ziemiecki R; Friedberg JW; Cerhan JR; Flowers CR; Link BK
Cancer; 2013 Dec; 119(23):4129-36. PubMed ID: 24006156
[TBL] [Abstract][Full Text] [Related]
28. Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment.
Arcaini L; Colombo N; Passamonti F; Burcheri S; Orlandi E; Brusamolino E; Della Porta M; Rumi E; Montanari F; Pascutto C; Paulli M; Lazzarino M
Leuk Res; 2006 Mar; 30(3):277-82. PubMed ID: 16112730
[TBL] [Abstract][Full Text] [Related]
29. The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi.
Rossi G; Marcheselli L; Dondi A; Bottelli C; Tucci A; Luminari S; Arcaini L; Merli M; Pulsoni A; Boccomini C; Puccini B; Micheletti M; Martinelli G; Rossi A; Zilioli VR; Bozzoli V; Balzarotti M; Bolis S; Cabras MG; Federico M
Am J Hematol; 2015 Jan; 90(1):56-61. PubMed ID: 25327841
[TBL] [Abstract][Full Text] [Related]
30. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.
Wong-Sefidan I; Byrtek M; Zhou X; Friedberg JW; Flowers CR; Zelenetz AD; Dawson KL; Reid E
Leuk Lymphoma; 2017 Apr; 58(4):809-815. PubMed ID: 27562750
[TBL] [Abstract][Full Text] [Related]
31. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
[TBL] [Abstract][Full Text] [Related]
32. Idelalisib for Treatment of Relapsed Follicular Lymphoma and Chronic Lymphocytic Leukemia: A Comparison of Treatment Outcomes in Clinical Trial Participants vs Medicare Beneficiaries.
Bird ST; Tian F; Flowers N; Przepiorka D; Wang R; Jung TH; Kessler Z; Woods C; Kim B; Miller BW; Wernecke M; Kim C; McKean S; Gelperin K; MaCurdy TE; Kelman JA; Graham DJ
JAMA Oncol; 2020 Feb; 6(2):248-254. PubMed ID: 31855259
[TBL] [Abstract][Full Text] [Related]
33. Rituximab Improves the Outcome of Patients With Grade 3 Follicular Lymphoma Receiving Anthracycline-Based Therapy.
Yuan J; Greiner TC; Fu K; Smith LM; Aoun P; Chan WC; Bierman PJ; Bociek RG; Vose JM; Armitage JO; Weisenburger DD
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):488-497.e2. PubMed ID: 28842137
[TBL] [Abstract][Full Text] [Related]
34. The 3q27 and 18q21 translocations for follicular lymphoma and diffuse large B-cell lymphoma in the rituximab era.
Watanabe R; Tomita N; Matsumoto C; Hattori Y; Matsuura S; Takasaki H; Hashimoto C; Fujita H; Fujisawa S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):107-14. PubMed ID: 23995106
[TBL] [Abstract][Full Text] [Related]
35. Autologous Stem Cell Transplantation for Follicular Lymphoma: Favorable Long-Term Survival Irrespective of Pretransplantation Rituximab Exposure.
Jiménez-Ubieto A; Grande C; Caballero D; Yáñez L; Novelli S; Hernández-Garcia MT; Manzanares M; Arranz R; Ferreiro JJ; Bobillo S; Mercadal S; Galeo A; López Jiménez J; Moraleda JM; Vallejo C; Albo C; Pérez E; Marrero C; Magnano L; Palomera L; Jarque I; Martínez-Sánchez P; Martín A; Coria E; López-Guillermo A; Salar A; Lahuerta JJ
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1631-1640. PubMed ID: 28533060
[TBL] [Abstract][Full Text] [Related]
36. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
[TBL] [Abstract][Full Text] [Related]
37. Factors influencing outcome in advanced stage, low-grade follicular lymphoma treated at MD Anderson Cancer Center in the rituximab era.
Cheah CY; Chihara D; Ahmed M; Davis RE; Nastoupil LJ; Phansalkar K; Hagemeister FB; Fayad LE; Westin JR; Oki Y; Fanale MA; Romaguera JE; Wang ML; Lee H; Turturro F; Samaniego F; Rodriguez MA; Neelapu SS; Fowler NH
Ann Oncol; 2016 May; 27(5):895-901. PubMed ID: 26802151
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
39. Assessing the Effectiveness of Treatment Sequences for Older Patients With High-risk Follicular Lymphoma With a Multistate Model.
Çağlayan Ç; Terawaki H; Ayer T; Goldstein JS; Rai A; Chen Q; Flowers C
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):300-309.e5. PubMed ID: 30686772
[TBL] [Abstract][Full Text] [Related]
40. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]